These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25562771)

  • 1. Health care costs among renal cancer patients using pazopanib and sunitinib.
    Hansen RN; Hackshaw MD; Nagar SP; Arondekar B; Deen KC; Sullivan SD; Ramsey SD
    J Manag Care Spec Pharm; 2015 Jan; 21(1):37-44, 44a-d. PubMed ID: 25562771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
    Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD
    J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
    MacLean E; Mardekian J; Cisar LA; Hoang CJ; Harnett J
    J Manag Care Spec Pharm; 2016 Aug; 22(8):979-90. PubMed ID: 27459661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Costs Among Renal Cancer Patients Using Pazopanib and Sunitinib.
    MacLean EA; Sandin R; Mardekian J
    J Manag Care Spec Pharm; 2015 Sep; 21(9):841-3. PubMed ID: 26308231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain.
    Villa G; Hernández-Pastor LJ
    BMC Cancer; 2013 Sep; 13():399. PubMed ID: 24004638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
    N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.
    Nazha S; Tanguay S; Kapoor A; Jewett M; Kollmannsberger C; Wood L; Bjarnason GAG; Heng D; Soulières D; Reaume MN; Basappa N; Lévesque E; Dragomir A
    Clin Drug Investig; 2018 Dec; 38(12):1155-1165. PubMed ID: 30267257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
    Ravasio R; Ortega C; Sabbatini R; Porta C
    Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients.
    Racsa PN; Whisman TR; Worley K
    Curr Med Res Opin; 2015; 31(10):1933-40. PubMed ID: 26368665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis.
    Deng H; Huang Y; Hong Z; Yuan X; Cao Z; Wei Y; Zhang W
    BMC Cancer; 2019 May; 19(1):489. PubMed ID: 31122210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
    Amdahl J; Diaz J; Sharma A; Park J; Chandiwana D; Delea TE
    PLoS One; 2017; 12(6):e0175920. PubMed ID: 28636648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
    Byfield SA; McPheeters JT; Burton TM; Nagar SP; Hackshaw MD
    J Manag Care Spec Pharm; 2015 Jun; 21(6):515-22. PubMed ID: 26011553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].
    Trump D
    Urol Oncol; 2016 May; 34(5):251. PubMed ID: 25937427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
    Beaumont JL; Salsman JM; Diaz J; Deen KC; McCann L; Powles T; Hackshaw MD; Motzer RJ; Cella D
    Cancer; 2016 Apr; 122(7):1108-15. PubMed ID: 27000445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.
    Kilonzo M; Hislop J; Elders A; Fraser C; Bissett D; McClinton S; Mowatt G; Vale L
    Pharmacoeconomics; 2013 Jan; 31(1):15-24. PubMed ID: 23329590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
    Capri S; Porta C; Delea TE
    Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.